- Beijing Tiantan achieved a net income of 1.55 billion yuan for the fiscal year.
- The company’s total revenue for the fiscal year was 6.03 billion yuan.
- Analysts are optimistic about Beijing Tiantan, with 18 buy recommendations.
- There are no hold or sell recommendations for Beijing Tiantan, indicating strong confidence from analysts.
A look at Beijing Tiantan Biological Products Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Beijing Tiantan Biological Products Corporation Limited, a company specializing in researching, developing, and commercializing biological products, has been rated using Smartkarma Smart Scores across key factors. With a Growth score of 4 and a Resilience score of 5, the company shows promising signs of expansion and durability in the market. This suggests that Beijing Tiantan Biological Products is well-positioned for long-term success and can weather potential challenges.
While the Value and Momentum scores are moderate at 3, indicating a stable but not exceptional performance in these areas, the Dividend score of 2 suggests that the company may have room for improvement in terms of rewarding investors. Overall, Beijing Tiantan Biological Products shows strong potential for growth and resilience in the biological products sector, backed by its research and commercialization efforts in the field of vaccines and hepatitis treatment.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
